Market Overview

AbbVie To Acquire Allergan In $63B Deal

AbbVie To Acquire Allergan In $63B Deal

Drugmaker AbbVie Inc (NYSE: ABBV) has reached a deal to acquire Allergan (NYSE: AGN) for $63 billion.

Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total of $188.24 per Allergan share.

The acquisition will provide annual pre-tax synergies and other cost reductions of at least $2 billion in year three.

"AbbVie is expected to generate significant annual operating cash flow, which will support a debt reduction target of $15 to $18 billion before the end of 2021, while also enabling a continued commitment to Baa2/BBB or better credit rating and continued dividend growth," the companies said in a press release.

AbbVie shares traded down 8.22% at $72 in Tuesday's pre-market session. Allergan shares traded higher by 29.6% at $167.88.

Related Links:

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale

7 Stocks To Watch For June 25, 2019

Photo courtesy of Allergan.

Posted-In: M&A News Health Care Top Stories General Best of Benzinga


Related Articles (AGN + ABBV)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at